Talaris Therapeutics Stock Gross Profit
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Talaris Therapeutics fundamentals help investors to digest information that contributes to Talaris Therapeutics' financial success or failures. It also enables traders to predict the movement of Talaris Stock. The fundamental analysis module provides a way to measure Talaris Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talaris Therapeutics stock.
Talaris |
Talaris Therapeutics Company Gross Profit Analysis
Talaris Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Talaris Therapeutics reported 0.0 of gross profit. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Talaris Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talaris Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics of similar companies.Talaris Therapeutics is currently under evaluation in gross profit category among its peers.
Talaris Fundamentals
| Return On Equity | -0.42 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (28.92 M) | |||
| Shares Outstanding | 42.81 M | |||
| Shares Owned By Insiders | 11.90 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 340.1 K | |||
| Price To Book | 0.28 X | |||
| EBITDA | (74.31 M) | |||
| Net Income | (73.89 M) | |||
| Cash And Equivalents | 207.11 M | |||
| Cash Per Share | 4.97 X | |||
| Total Debt | 2.88 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 28.92 X | |||
| Book Value Per Share | 3.49 X | |||
| Cash Flow From Operations | (60.86 M) | |||
| Short Ratio | 4.01 X | |||
| Earnings Per Share | (1.97) X | |||
| Target Price | 20.0 | |||
| Number Of Employees | 84 | |||
| Beta | 2.18 | |||
| Market Capitalization | 125.73 M | |||
| Total Asset | 193.72 M | |||
| Retained Earnings | (164.74 M) | |||
| Working Capital | 174.15 M | |||
| Z Score | 24.78 | |||
| Net Asset | 193.72 M |
About Talaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Talaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |